Safety and Tolerability of Multimodal Therapy (Ivermectin, Doxycycline, Vitamin C, Vitamin D, and Zinc) With or Without Famotidine in Australian Patients With COVID-19 Infection: A Pilot Cohort Trial.

What Was Tested

The paper reports a study of Vitamin D, K2, Magnesium and Zinc, published as a randomized controlled trial.

To assess the safety and tolerability of a combination of repurposed drugs and supplements in the early therapy of acute nonhospitalized COVID-19 illness.

Why It Was Studied

In 2020, COVID-19 caused by the SARS-CoV-2 emerged as a global pandemic.

Who Took Part

By PubMed's age tags, the people studied were adults, middle-aged adults and older adults, both men and women.

How the Study Was Run

In design terms this was a randomized, multicenter and pilot study.

The participants were allocated by chance, so the Vitamin D, K2, Magnesium and Zinc group and the comparison group should start out alike.

Running at several centres spread the Vitamin D, K2, Magnesium and Zinc study over different clinics and patient groups.

It is described as a pilot, a small early test of whether a larger Vitamin D, K2, Magnesium and Zinc study would be practical.

A multicenter pilot cohort study was undertaken.

What Was Measured

PubMed files the paper under topics including Ascorbic Acid, Australia, Cohort Studies, COVID-19, COVID-19 Drug Treatment, Famotidine and Ivermectin.

The authors tagged it with the keywords doxycycline, hospitalization and respiratory symptoms.

What This Means in Plain Language

The paper is a randomized, multicenter and pilot study of Vitamin D, K2, Magnesium and Zinc.

The abstract goes on to report its results in about 8 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 2026 (American journal of therapeutics), a journal based in United States.

More context: the Vitamin D, K2, Magnesium and Zinc compound page, all human trials.